SCHEMBL699775

SCHEMBL699775

O=C(O)C1CCCC1C(=O)N1CCCCC1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.54
▸ CTSB P07858 1/20 0.49
▸ CTSS P25774 1/20 0.49
▸ CTSK P43235 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.43
▸ TSHR P16473 1/20 0.43
▸ PEPD P12955 1/20 0.42
▸ TFPI2 P48307 1/20 0.42
▸ HSD11B1 P28845 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ADAM10 O14672 1/20 0.39
▸ ERBB2 P04626 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ SIGMAR1 Q99720 1/20 0.39
▸ ACE P12821 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18485325 0.96 HPGD (0.54) HPGDCTSBCTSSCTSKALDH1A1
SCHEMBL1163992 0.94 HPGD (0.56) HPGDCTSBCTSSCTSKALDH1A1
SCHEMBL1163991 0.94 HPGD (0.56) HPGDCTSBCTSSCTSKALDH1A1
SCHEMBL16424491 0.91 HPGD (0.52) HPGDCTSBCTSSCTSKALDH1A1
SCHEMBL3239184 0.82 CHRNB2 (0.55) TSHRPEPDADAM10ERBB2MMP2
SCHEMBL703966 0.82 CHRNB2 (0.55) TSHRPEPDADAM10ERBB2MMP2
SCHEMBL2686310 0.79 HPGD (0.48) HPGDCTSBCTSSCTSKALDH1A1
SCHEMBL29012248 0.79 CHRNB2 (0.55) CTSBCTSSCTSKALDH1A1TSHR
SCHEMBL5761060 0.79 ALDH1A1 (0.43) HPGDALDH1A1TSHRSMN1; SMN2ADAM10
SCHEMBL31207070 0.79 CTSB (0.57) CTSBCTSSCTSKALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124766-B2 Inhibitors of diacylglycerol acyltransferase MADRIGAL PHARMACEUTICALS, INC. (US) 2012-02-28 — — US claimed
CN-102239165-A Inhibitors of diacylglycerol acyltransferase VIA PHARMACEUTICALS INC 2011-11-09 — — CN claimed
EP-2367817-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE Via Pharmaceuticals, Inc. (US) 2011-09-28 — — EP claimed
WO-2010065310-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE VIA PHARMACEUTICALS, INC (US) 2010-06-10 — — WO claimed
US-20100145047-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE MADRIGAL PHARMACEUTICALS, INC. 2010-06-10 — — US claimed
US-8124766-B2 Inhibitors of diacylglycerol acyltransferase MADRIGAL PHARMACEUTICALS, INC. (US) 2012-02-28 — — US disclosed
CN-102239165-A Inhibitors of diacylglycerol acyltransferase VIA PHARMACEUTICALS INC 2011-11-09 — — CN disclosed
EP-2367817-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE Via Pharmaceuticals, Inc. (US) 2011-09-28 — — EP disclosed
WO-2010065310-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE VIA PHARMACEUTICALS, INC (US) 2010-06-10 — — WO disclosed
US-20100145047-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE MADRIGAL PHARMACEUTICALS, INC. 2010-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100145047-A1 INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE DGAT2, DGAT1, LCAT HPGD 818/4885CTSB 2698/4885CTSS 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback